Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2019 01:00 ET | Source: INNATE PHARMA

Innate Pharma à l’AACR 2019 : nouvelles données sur la prochaine génération d’immunothérapies des cancers

INNATE PHARMA A L’AACR 2019 : NOUVELLES DONNÉES SUR LA PROCHAINE GÉNÉRATION D’IMMUNOTHÉRAPIES DES CANCERS Nouvelles données précliniques sur IPH5201 (anti-CD39) et IPH5301 (anti-CD73) ciblant la...
April 01, 2019 01:00 ET | Source: INNATE PHARMA

Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting

INNATE PHARMA HIGHLIGHTS NEXT GENERATION OF CANCER IMMUNOTHERAPIES AT THE AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) 2019 ANNUAL MEETING New preclinical data highlights IPH5201 (anti-CD39) and...
December 03, 2018 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
June 20, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™

SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
May 17, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer

SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
May 16, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy

Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16,...
May 02, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016

SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
February 25, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016

SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...